This publication was downloaded for exclusive use by: Aiman.Mohamad@macquarie.com

Flashnote 19 August 2020

# EQUITIES

SCGB MK Price (at 14:46, 18 Aug 2020 GMT)		Neutral RM1.79
Valuation - PER	RM	1.46-2.13
12-month target	RM	1.80
Upside/Downside	%	+0.6
12-month TSR	%	+4.5
Volatility Index		Medium
GICS sector	Ca	apital Goods
Market cap	RMm	2,314
Market cap	US\$m	552
Free float	%	25
30-day avg turnover	US\$m	0.2
Number shares on issue	m	1,293

#### Investment fundamentals

Year end 31 Dec		2019A	2020E	2021E	2022E
Revenue	m	1,768.7	1,535.2	2,374.2	2,395.6
EBITDA	m	181.3	127.8	200.3	218.9
EBIT	m	141.0	77.5	145.4	160.6
Reported profit	m	129.3	72.9	134.8	150.3
Adjusted profit	m	129.3	72.9	134.8	150.3
EPS rep	sen	10.0	5.6	10.4	11.6
EPS rep growth	%	-10.6	-43.7	84.9	11.6
EPS adj	sen	10.0	5.6	10.4	11.6
EPS adj growth	%	-10.6	-43.7	84.9	11.6
PER rep	х	17.9	31.8	17.2	15.4
PER adj	х	17.9	31.8	17.2	15.4
Total DPS	sen	7.0	5.0	8.0	8.0
Total div yield	%	3.9	2.8	4.5	4.5
ROA	%	7.7	4.2	7.6	7.7
ROE	%	21.3	11.7	20.9	21.7
EV/EBITDA	х	10.3	14.3	9.1	8.3
Net debt/equity	%	-65.0	-78.2	-81.5	-76.4
P/BV	х	3.7	3.7	3.5	3.2

#### SCGB MK rel KLCI performance, & rec history



Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, August 2020 (all figures in MYR unless noted)

## Analysts

Macquarie Capital Securities (Malaysia) Sdn. Bhd.



Aiman Mohamad +60 3 2059 8986 aiman.mohamad@macquarie.com Malaysia

# **Sunway Construction Group (SCGB MK)** 2Q20 results miss: loss-making precast alleviated by two contract wins

# Event

- SunCon reported its 2Q20 results with adj. PAT of RM2.2mn (-93% YoY, -87% QoQ) backed by revenue of RM140.2mn (-68% YoY, -62% QoQ). 1H20 adj. PAT was at RM18.5mn (-71% YoY), tracking well below MQ and Bloomberg consensus estimates at 25% and 21%, respectively. 1H20 revenue was at RM506mn (-43% YoY), tracking below MQ and consensus estimates at 33% and 31%, respectively. Results missed due to the low construction activity during Malaysia's lockdown in 2Q20.
- On the flipside, SunCon recorded another two contract wins worth RM344mn and RM403mn, respectively, from parent Sunway Berhad. The order wins recorded yesterday have taken YTD order win tally to RM1.472bn. We believe the order wins of up to RM2bn in FY20E are well priced in; thus any share price outperformance is likely only to be driven by SunCon's ability to surpass the mark.

# Impact

- Earnings fell short but we expect recovery in 2H20E, mainly driven by real estate projects. While 1H20 earnings are only at 25% of our FY20E adj. PAT estimates of RM73mn, we expect earnings in 3-4QE will recover strongly as construction projects resume their activities. Historically, SunCon has booked RM30-35mn of quarterly earnings, and thus we believe the earnings shortfall will be recovered in 2H20E.
- Order wins priced; we expect another RM500mn order wins from the parent company in 2H20. We highlighted previously that FY20E order wins will be mainly driven by in-house order wins from Sunway Berhad. Having secured close to RM1.5bn YTD (c.40% external wins), we expect Sunway Berhad to drive another RM500mn of order wins for the remainder of the FY. Existing order book stood at RM5.4bn as at 2Q20-end, before taking into account the RM747mn of new orders secured yesterday.
- Dividends came short of our expectations. SunCon declared a first interim DPS of 1.25sen, 50% short of our expectations. We initially expected SunCon to pay up to 2.5sen DPS in 1H20 and 2H20, respectively, taking FY20E's payout ratio to 88%. On a weighted average basis, SunCon's payout ratio is at 61% since listing.
- Losses in precast division are more than we expected; construction division performance in-line. As at 1H20, SunCon's precast division booked an LBIT of RM2mn, taking the EBIT margin to -5% (vs.1.6% in 1H19); this is wider than the -1% we expected for FY20E. Recovery for this division hinges on the ability for the HDB projects in Singapore to progress per normal. We understand only 25% of SunCon's projects in Singapore are currently running, thus have dragged down the division's performance. Meanwhile construction division booked EBIT margin of 4.4% in 1H20 (vs. 9.2% 1H19). As we expect earnings to recover in 2H20, construction division's margins should improve and come closer to our estimate of 5.2% for FY20E.

# Action and recommendation

• Neutral rating maintained.

# **Macquarie Research**

# Important disclosures:

# **Recommendation definitions**

Macquarie – Asia and USA Outperform - expected return >10% Neutral - expected return from -10% to +10% Underperform - expected return <-10%

# Macquarie - Australia/New Zealand

Outperform - expected return >10% Neutral - expected return from 0% to 10% Underperform - expected return <0%

Note: expected return is reflective of a Medium Volatility stock and should be assumed to adjust proportionately with volatility risk

#### Volatility index definition\*

This is calculated from the volatility of historical price movements.

Very high-highest risk - Stock should be expected to move up or down 60-100% in a year - investors should be aware this stock is highly speculative.

High - stock should be expected to move up or down at least 40-60% in a year - investors should be aware this stock could be speculative.

Medium - stock should be expected to move up or down at least 30-40% in a year.

Low-medium - stock should be expected to move up or down at least 25-30% in a year.

Low – stock should be expected to move up or down at least 15-25% in a year Applicable to select stocks in Asia/Australia/NZ

Recommendations - 12 months

Note: Quant recommendations may differ from Fundamental Analyst recommendations

## Recommendation proportions - For quarter ending 30 June 2020

	AU/NZ	Asia	USA	
Outperform	49.82%	60.45%	66.29%	(for global coverage by Macquar

Outperform	49.82%	60.45%	66.29%	(for global coverage by Macquarie, 4.18% of stocks followed are investment banking clients)
Neutral	35.09%	23.46%	33.71%	(for global coverage by Macquarie, 4.41% of stocks followed are investment banking clients)
Underperform	15.09%	16.09%	0.00%	(for global coverage by Macquarie, 3.21% of stocks followed are investment banking clients)

# SCGB MK vs KLCI, & rec history



Note: Recommendation timeline - if not a continuous line, then there was no Macquarie coverage at the time or there was an embargo period. Source: FactSet, Macquarie Research, August 2020

#### 12-month target price methodology

SCGB MK: RM1.80 based on a PER methodology

# Company-specific disclosures:

SCGB MK: Macquarie may be an Issuer of Structured Warrants on securities mentioned in this report

Important disclosure information regarding the subject companies covered in this report is available publicly at

www.macquarie.com/research/disclosures. Clients receiving this report can additionally access previous recommendations (from the year prior to publication of this report) issued by this report's author at https://www.macquarieinsights.com.

Date	Stock Code (BBG code)	Recommendation	Target Price
29-Jul-2020	SCGB MK	Neutral	RM1.80
14-Apr-2020	SCGB MK	Outperform	RM2.00
25-Jul-2019	SCGB MK	Outperform	RM2.50
14-May-2019	SCGB MK	Neutral	RM2.00
11-Jan-2019	SCGB MK	Neutral	RM1.40
20-Jul-2018	SCGB MK	Neutral	RM2.00
19-Apr-2018	SCGB MK	Outperform	RM2.60
06-Oct-2017	SCGB MK	Outperform	RM2.80

#### Target price risk disclosures:

SCGB MK: Any inability to compete successfully in their markets may harm the business. This could be a result of many factors which may include geographic mix and introduction of improved products or service offerings by competitors. The results of operations may be materially affected by global economic conditions generally, including conditions in financial markets. The company is exposed to market risks, such as changes in interest rates, foreign exchange rates and input prices. From time to time, the company will enter into transactions, including transactions in derivative instruments, to manage certain of these exposures.

#### Sensitivity analysis:

Clients receiving this report can request access to a model which allows for further in-depth analysis of the assumptions used, and recommendations made, by the author relating to the subject companies covered. To request access please contact insights@macquarie.com.

## Analyst certification:

We hereby certify that all of the views expressed in this report accurately reflect our personal views about the subject company or companies and its or their securities. We also certify that no part of our compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report. The Analysts responsible for preparing this report receive compensation from Macquarie that is based upon various factors including Macquarie Group Ltd total revenues, a portion of which are generated by Macquarie Group's Investment Banking activities.

#### General disclaimers:

Macquarie Securities (Australia) Ltd; Macquarie Capital (Europe) Ltd; Macquarie Capital (USA) Inc; Macquarie Capital Limited, Taiwan Securities Branch; Macquarie Capital Securities (Singapore) Pte Ltd; Macquarie Securities (NZ) Ltd; Macquarie Capital Securities (India) Pvt Ltd; Macquarie

# **Financial definitions**

All "Adjusted" data items have had the following adjustments made: Added back: goodwill amortisation, provision for

catastrophe reserves, IFRS derivatives & hedging, IFRS impairments & IFRS interest expense Excluded: non recurring items, asset revals, property revals, appraisal value uplift, preference dividends & minority interests

# EPS = adjusted net profit / efpowa\*

ROA = adjusted ebit / average total assets ROA Banks/Insurance = adjusted net profit /average total assets ROE = adjusted net profit / average shareholders funds

Gross cashflow = adjusted net profit + depreciation equivalent fully paid ordinary weighted average number of shares

All Reported numbers for Australian/NZ listed stocks are modelled under IFRS (International Financial Reporting Standards).

# **Macquarie Research**

# Sunway Construction Group (SCGB MK)

Capital Securities (Malaysia) Sdn Bhd; Macquarie Securities Korea Limited and Macquarie Securities (Thailand) Ltd are not authorized deposit-taking institutions for the purposes of the Banking Act 1959 (Commonwealth of Australia), and their obligations do not represent deposits or other liabilities of Macquarie Bank Limited ABN 46 008 583 542 (MBL) or MGL. MBL does not guarantee or otherwise provide assurance in respect of the obligations of any of the above mentioned entities. MGL provides a guarantee to the Monetary Authority of Singapore in respect of the obligations and liabilities of Macquarie Capital Securities (Singapore) Pte Ltd for up to SGD 35 million. This research has been prepared for the general use of the wholesale clients of the Macquarie Group and must not be copied, either in whole or in part, or distributed to any other person. If you are not the intended recipient you must not use or disclose the information in this research in any way. If you received it in error, please tell us immediately by return e-mail and delete the document. We do not guarantee the integrity of any e-mails or attached files and are not responsible for any changes made to them by any other person. MGL has established and implemented a conflicts policy at group level (which may be revised and updated from time to time) (the "Conflicts Policy") pursuant to regulatory requirements which sets out how we must seek to identify and manage all material conflicts of interest. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any transaction. In preparing this research, we did not take into account your investment objectives, financial situation or particular needs. Macquarie salespeople, traders and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions which are contrary to the opinions expressed in this research. Macquarie Research produces a variety of research products including, but not limited to, fundamental analysis, macro-economic analysis, quantitative analysis, and trade ideas. Recommendations contained in one type of research product may differ from recommendations contained in other types of research, whether as a result of differing time horizons, methodologies, or otherwise. Before making an investment decision on the basis of this research, you need to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of your particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. This research is based on information obtained from sources believed to be reliable but we do not make any representation or warranty that it is accurate, complete or up to date. We accept no obligation to correct or update the information or opinions in it. Opinions expressed are subject to change without notice. No member of the Macquarie Group accepts any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Clients should contact analysts at, and execute transactions through, a Macquarie Group entity in their home jurisdiction unless governing law permits otherwise. The date and timestamp for above share price and market cap is the closed price of the price date. #CLOSE is the final price at which the security is traded in the relevant exchange on the date indicated. Members of the Macro Strategy team are Sales & Trading personnel who provide desk commentary that is not a product of the Macquarie Research department or subject to FINRA Rule 2241 or any other regulation regarding independence in the provision of equity research.

## Country-specific disclaimers:

Australia: In Australia, research is issued and distributed by Macquarie Securities (Australia) Ltd (AFSL No. 238947), a participating organization of the Australian Securities Exchange. Macquarie Securities (Australia) Limited staff involved with the preparation of research have regular interaction with companies they cover. Additionally, Macquarie Group Limited does and seeks to do business with companies covered by Macquarie Research. There are robust information barriers in place to protect the independence of Macquarie Research's product. However, recipients of Macquarie Research should be aware of this potential conflict of interest. New Zealand: In New Zealand, research is issued and distributed by Macquarie Securities (NZ) Ltd, a NZX Firm. United Kingdom and the EEA: In the United Kingdom and the European Economic Area, research is distributed by Macquarie Capital (Europe) Ltd, which is authorised and regulated by the Financial Conduct Authority (No. 193905). Hong Kong & Mainland China: In Hong Kong, research is issued and distributed by Macquarie Capital Limited, which is licensed and regulated by the Securities and Futures Commission. In Mainland China, Macquarie Securities (Australia) Limited Shanghai Representative Office only engages in non-business operational activities excluding issuing and distributing research. Only non-A share research is distributed into Mainland China by Macquarie Capital Limited. Japan: In Japan, research is Issued and distributed by Macquarie Capital Securities (Japan) Limited, a member of the Tokyo Stock Exchange, Inc. and Osaka Exchange, Inc. (Financial Instruments Firm, Kanto Financial Bureau (kin-sho) No. 231, a member of Japan Securities Dealers Association). India, research is issued and distributed by Macquarie Capital Securities (India) Pvt. Ltd. (CIN: U65920MH1995PTC090696), 92, Level 9, 2 North Avenue, Maker Maxity, Bandra Kurla Complex, Bandra (East), Mumbai – 400 051, India, which is a SEBI registered Research Analyst having registration no. INH000000545. During the past 12 months, Macquarie Group Limited or one of its affiliates may have provided securities services to companies mentioned in this report for which it received compensation for Broking services. Malaysia: In Malaysia, research is issued and distributed by Macquarie Capital Securities (Malaysia) Sdn. Bhd. (Company registration number: 199801007342 (463469-W)) which is a Participating Organisation of Bursa Malaysia Berhad and a holder of Capital Markets Services License issued by the Securities Commission. Taiwan: In Taiwan, research is issued and distributed by Macquarie Capital Limited, Taiwan Securities Branch, which is licensed and regulated by the Financial Supervisory Commission. No portion of the report may be reproduced or quoted by the press or any other person without authorisation from Macquarie. Nothing in this research shall be construed as a solicitation to buy or sell any security or product. The recipient of this report shall not engage in any activities which may give rise to potential conflicts of interest to the report. Research Associate(s) in this report who are registered as Clerks only assist in the preparation of research and are not engaged in writing the research. Macquarie may be in past one year or now being an Issuer of Structured Warrants on securities mentioned in this report. Thailand: In Thailand, research is produced, issued and distributed by Macquarie Securities (Thailand) Ltd. Macquarie Securities (Thailand) Ltd. is a licensed securities company that is authorized by the Ministry of Finance, regulated by the Securities and Exchange Commission of Thailand and is an exchange member of the Stock Exchange of Thailand. The Thai Institute of Directors Association has disclosed the Corporate Governance Report of Thai Listed Companies made pursuant to the policy of the Securities and Exchange Commission of Thailand. Macquarie Securities (Thailand) Ltd does not endorse the result of the Corporate Governance Report of Thai Listed Companies but this Report can be accessed at: http://www.thaiiod.com/en/publications.asp?type=4. South Korea: In South Korea, unless otherwise stated, research is prepared, issued and distributed by Macquarie

Securities Korea Limited, which is regulated by the Financial Supervisory Services. Information on analysts in MSKL is disclosed at http://dis.kofia.or.kr/websquare/index.jsp?w2xPath=/wq/fundMgr/DISFundMgrAnalystStut.xml&divisionId=

MDIS03002001000000&serviceId=SDIS03002001000. Singapore: In Singapore, research is issued and distributed by Macquarie Capital Securities (Singapore) Pte Ltd (Company Registration Number: 198702912C), a Capital Markets Services license holder under the Securities and Futures Act to deal in securities and provide custodial services in Singapore. Pursuant to the Financial Advisers (Amendment) Regulations 2005, Macquarie Capital Securities (Singapore) Pte Ltd is exempt from complying with sections 25, 27 and 36 of the Financial Advisers Act. All Singapore-based recipients of research produced by Macquarie Capital (USA) Inc. represent and warrant that they are institutional investors as defined in the Securities and Futures Act. Singapore recipients should contact Macquarie Capital Securities (Singapore) Pte Ltd at +65 6601 0888 for matters arising from, or in connection with, this report. United States: In the United States, research is issued and distributed by Macquarie Capital (USA) Inc., which is a registered brokerdealer and member of FINRA. Macquarie Capital (USA) Inc, accepts responsibility for the content of each research report prepared by one of its non-US affiliates when the research report is distributed in the United States by Macquarie Capital (USA) Inc. Macquarie Capital (USA) Inc.'s affiliate's analysts are not registered as research analysts with FINRA, may not be associated persons of Macquarie Capital (USA) Inc., and therefore may not be subject to FINRA rule restrictions on communications with a subject company, public appearances, and trading securities held by a research analyst account. Information regarding futures is provided for reference purposes only and is not a solicitation for purchases or sales of futures. Any persons receiving this report directly from Macquarie Capital (USA) Inc. and wishing to effect a transaction in any security described herein should do so with Macquarie Capital (USA) Inc. Important disclosure information regarding the subject companies covered in this report is available at

www.macquarie.com/research/disclosures, or contact your registered representative at 1-888-MAC-STOCK, or write to the Supervisory Analysts, Research Department, Macquarie Capital (USA) Inc, 125 W.55th Street, New York, NY 10019. Canada: In Canada, research is distributed by Macquarie Capital Markets Canada Ltd., a (i) member of the Investment Industry Regulatory Organization of Canada (IIROC) and the Canadian Investor Protection Fund, and (ii) participating organisation of the Toronto Stock Exchange, TSX Venture Exchange & Montréal Exchange. Important disclosure information regarding the subject companies covered in this report is available at www.macquarie.com/research/disclosures. IIROC Rule 3400 Disclosures can be obtained by writing to Macquarie Capital Markets Canada Ltd., 181 Bay St. Suite 3100, Toronto, ON M5J2T3. © Macquarie Group

**Equities** 

# **Asia Research**

## Head of Equity Research

Jake Lynch (Asia) Hiroyuki Sakaida (Japan) Jayden Vantarakis (ASEAN) Strategy, Country Viktor Shvets (Asia, Global)

Viktor Shvets (Asia, Global)	(852) 3922 3883
David Ng (China, Hong Kong)	(852) 3922 1291
Hiroyuki Sakaida (Japan)	(813) 3512 6695
Daniel Kim (Korea)	(822) 3705 8641
Jeffrey Ohlweiler (Taiwan)	(8862) 2734 7512
Jayden Vantarakis	
(ASEAN, Singapore)	(6221) 2598 8310
Ari Jahja (Indonesia)	(6221) 2598 8366
Prem Jearajasingam (Malaysia)	(603) 2059 8989
Gilbert Lopez (Philippines)	(632) 857 0892
Peach Patharavanakul (Thailand)	(662) 694 7753
Aditya Suresh (India)	(852) 3922 1265
Charles Yonts (Asia ESG)	(852) 3922 5832
Felix Rusli (Asia Product)	(852) 3922 4283

## Technology

Nicolas Baratte (Asia)
Damian Thong (Asia)
Jeffrey Ohlweiler (Greater China)
Patrick Liao (Greater China)
Cherry Ma (Greater China)
Erica Chen (Greater China)
Kaylin Tsai (Greater China)
Hiroshi Taguchi (Japan)
Daniel Kim (Korea)
Sonny Lee (Korea)
Abhishek Bhandari (India)

#### Telecoms

Nicolas Baratte (Asia) Hiroshi Yamashina (Japan) Andy Kim (Korea) Prem Jearajasingam (ASEAN) Kervin Sisayan (Philippines)

#### Internet, Media and Software

Han Joon Kim (Asia)
John Wang (China, Hong Kong)
Frank Chen (China, Hong Kong)
Ellie Jiang (China, Hong Kong)
Andy Kim (Korea)
Alankar Garude (India)

#### Consumer, Gaming

(852) 3922 3583

(813) 3512 6695

(852) 3922 5801

(813) 3512 7877

(8862) 2734 7512

(8862) 2734 7515 (852) 3922 5800

(8621) 2412 9024

(8862) 2734 7523

(813) 3512 7867

(822) 3705 8641

(822) 3705 8678

(9122) 6720 4088

(852) 3922 5801

(813) 3512 5968

(822) 3705 8690

(603) 2059 8989

(852) 3922 5926

(852) 3922 3578

(852) 3922 1433

(852) 3922 4110 (822) 3705 8690 (9122) 6720 4134

(632) 857 0893

(6221) 2598 8310

consumer, Gaming	
Linda Huang (Asia) Terence Chang (China, Hong Kong) Sunny Chow (China, Hong Kong) Edward Engel (China, Hong Kong) Leon Rapp (Japan) Kwang Cho (Korea) Amit Sinha (India) Denise Soon (Malaysia) Karisa Magpayo (Philippines) Chalinee Congmuang (Thailand) Healthcare and Pharmaceutio	(852) 3922 4068 (852) 3922 3581 (852) 3922 3768 (852) 3922 5750 (813) 3512 7879 (822) 3705 4953 (9122) 6720 4085 (603) 2059 8845 (632) 857 0899 (662) 694 7993 <b>cals</b>
David Ng (China, Hong Kong) Xiang Gao (China, Hong Kong) Corinne Jian (China) Mi Hyun Kim (Korea) Alankar Garude (India) Ari Jahja (Indonesia)	(852) 3922 1291 (8621) 2412 9006 (8862) 2734 7522 (822) 3705 8689 (9122) 6720 4134 (6221) 2598 8366
Emerging Leaders	
Corinne Jian (Asia) Kwang Cho (Korea) Bo Denworalak (Thailand)	(8862) 2734 7522 (822) 3705 4953 (662) 694 7774
Banks and Financials	
Scott Russell (Asia) Dexter Hsu (China, Taiwan) Suresh Ganapathy (India) Nishant Shah (India) Jayden Vantarakis (ASEAN, Indonesia, Singapore) Ben Shane Lim (Malaysia) Gilbert Lopez (Philippines) Peach Patharavanakul (Thailand)	(852) 3922 3567 (8862) 2734 7530 (9122) 6720 4078 (9122) 6720 4099 (6221) 2598 8310 (603) 2059 8868 (632) 857 0892 (662) 694 7753
Property, REIT	
Kelvin Tam (China, Hong Kong) Masahiro Mochizuki (Japan) Richard Danusaputra (Indonesia) Aiman Mohamad (Malaysia) Kervin Sisayan (Philippines) Derrick Heng (Singapore) Bo Denworalak (Thailand) Abhishek Bhandari (India)	(852) 3922 1181 (813) 3512 7868 (6221) 2598 8368 (603) 2059 8986 (632) 857 0893 (65) 6601 0436 (662) 694 7774 (9122) 6720 4088

### **Oil, Gas and Petrochemicals**

;	Mark Wiseman (A Anna Park (Asia) Yasuhiro Nakada Corinne Jian (Tai Ben Shane Lim (N Yupapan Polporn Aditya Suresh (In	(612) 8232 8417 (822) 3705 8669 (813) 3512 7862 (8862) 2734 7522 (603) 2059 8868 (662) 694 7729 (852) 3922 1265			
	Basic Materia	lls, Commodities	6		
6	David Ching (China, Hong Kong) Harunobu Goroh (Japan) Yasuhiro Nakada (Japan) Anna Park (Korea) Ashish Jain (India)		(852) 3922 1823 (813) 3512 7886 (813) 3512 7862 (822) 3705 8669 (9122) 6720 4063		
2	Utilities, Renewables				
4 6 2	Hiroyuki Sakaida (Japan) Patrick Dai (China) Sean Hu (China, Hong Kong) Kerry Cheng (China) Karisa Magpayo (Philippines)		(813) 3512 6695 (8621) 2412 9082 (852) 3922 3571 (8621) 2412 9025 (632) 857 0899		
	Industrials, Autos, Transportation				
) 3 9 0	Patrick Dai (China) Eric Zong (China, Hong Kong) Allen Yuan (China, Hong Kong) Kunio Sakaida (Japan) James Hong (Korea) Corinne Jian (Taiwan) Zhiwei Foo (Singapore) Ajinkya Bhat (India)		(8621) 2412 9082 (852) 3922 4749 (8621) 2412 9009 (813) 3512 7873 (822) 3705 8661 (8862) 2734 7522 (65) 6601 0465 (9122) 6720 4052		
	Find our rese Macquarie: Refinitiv: Bloomberg: Factset: CapitallQ	arch at www.macquarieins www.refinitiv.com MAC GO http://www.factset. www.capitaliq.com	0		

# requests. **Email addresses**

FirstName.Surname@macquarie.com

Contact macresearch@macquarie.com for access

# Asia Sales

## **Regional Heads of Sales** Head of Asian Sales)

Christina Lee (Head of Asian
Alan Chen (HK/China)
Amelia Mehta (Singapore)
Paul Colaco (US)
Mothlib Miah (UK/Europe)
Sandeep Bhatia (India)
Janeman Latul (Indonesia)
Thomas Renz (Geneva)
Leslie Hoy (Japan)

(1 212) 231 2559 (852) 3922 2019 (65) 6601 0211 (1 415) 762 5003 (44 20) 3037 4893 (9122) 6720 4101 (6221) 2598 8303 (41 22) 818 7712 (813) 3512 7919

#### Tomohiro Takahashi (Japan) DJ Kwak (Korea) Nik Hadi (Malaysia) Gino C Rojas (Philippines)

Eric Lin (Taiwan) Angus Kent (Thailand)

#### Regional Heads of Sales cont'd (813) 3512 7823 (822) 3705 8608 (603) 2059 8888 (632) 857 0861 (8862) 2734 7590 (662) 694 7601

#### Sales Trading

Mark Weekes (Asia)	(852) 3922 2084
Stanley Dunda (Indonesia)	(6221) 515 1555
Edward Jones (Japan)	(813) 3512 7822
Suhaida Samsudin (Malaysia)	(603) 2059 8888
Michael Santos (Philippines)	(632) 857 0813
Mike Gray (New York)	(1 212) 231 2555
Justin Morrison (Singapore)	(65) 6601 0288
Brendan Rake (Thailand)	(662) 694 7707
Mike Keen (UK/Europe)	(44 20) 3037 4905
Susan Lin (Taiwan)	(886 2) 2734 7583